STAT+: For its first two medicines, EQRx abandons its bold strategy to lower drug prices

Changing the way cancer drugs are priced in the U.S. is apparently even harder than it sounds.

EQRx, a company founded to upend the costly U.S. system for pricing new drugs, said Thursday it would abandon that goal for the two products that are closest to the market.

Continue to STAT+ to read the full story…

This post was originally published on this site

Leave a Reply

error: Content is protected !!
Open chat
WhatsApp Now